JPRN-jRCT2080221603未知3 期
ong-term study of SYR-322
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点开始时间: 2011年10月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1. The subject is an outpatient.
- •2. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
排除标准
- •1. The subject has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
- •2. The subject is considered ineligible for the study for any other reason by the investigator or subinvestigator.
研究者
相似试验
未知
3 期
ong-term study of SYR-472Diabetes mellitusJPRN-jRCT2080221552TAKEDA PHARMACEUTICAL COMPANY LTD.622
未知
2 期
A phase II/III study of SYR-322 in subject with diabetesDiabetes mellitusJPRN-jRCT2080220871Takeda Pharmaceutical Company Limited
未知
2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a ThiazolidineJPRN-jRCT2080220568Takeda Pharmaceutical Company Limited240
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to a ThiazolidineType 2 diabetes mellitusJPRN-UMIN000001382Takeda Pharmaceutical Company Limited240
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to a MetformiType 2 diabetes mellitusJPRN-UMIN000001394Takeda Pharmaceutical Company Limited240